Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / July 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Denbury Inc. (NYSE: DEN)'s sale to ...
NEW YORK, NY / ACCESSWIRE / July 21, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ:FRG)'s ...
NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Equity Investment Life Holdi...
NEW YORK, NY / ACCESSWIRE / July 18, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NASDAQ:KD...
2023-07-17 10:05:21 ET NASDAQ: PRDS said soared +16.9% said in April that it was exploring an acquisition of the company started a review of strategic alternatives For further details see: Pardes Biosciences soars after co to be acquired by MediPacific
CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash ...
2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...
2023-05-05 16:33:00 ET Pardes Biosciences press release ( NASDAQ: PRDS ): Q1 GAAP EPS of -$0.30 beats by $0.11 . Pardes’ cash, cash equivalents and short-term investments as of March 31, 2023, were $172.2 million compared to $197.3 million as of December 31...
CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternativ...
2023-05-02 09:58:49 ET Summary Pardes Biosciences is a busted biopharma that is exploring strategic alternatives and trades at a wide 30% discount to its net cash. The company recently received a buyout proposal from its major shareholder/SPAC sponsor. Pardes Biosciences is li...
News, Short Squeeze, Breakout and More Instantly...
Pardes Biosciences Inc. Company Name:
PRDS Stock Symbol:
NASDAQ Market:
CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully comp...
As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. ...
NEW YORK, NY / ACCESSWIRE / August 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chase Corporation (NY...